MASSACHUSETTS GENERAL HOSPITAL

A Phase I/II clinical trial at UMass Chan Medical School demonstrated biochemical correction of GM2 gangliosidosis using dual vector gene therapy with minimal adverse reactions.

The progressive supranuclear palsy (PSP) market is experiencing significant growth driven by emerging therapies including AZP2006 and AMX0035, which are advancing through clinical trials with promising results.

Mass General Brigham has initiated two prospective clinical trials to evaluate Haystack MRD, a highly sensitive circulating tumor DNA test, for guiding postoperative treatment decisions in cutaneous squamous cell carcinoma and HPV-independent head and neck squamous cell carcinoma.

Harvard researchers found that people with Alzheimer's disease have 36% lower lithium levels in their prefrontal cortex compared to those without cognitive decline.

A retrospective study of 110 men with obesity or Type 2 diabetes found that GLP-1 receptor agonists like semaglutide and tirzepatide can naturally restore testosterone levels over 18 months of treatment.

Dr. Alya A. Arabi from United Arab Emirates University has been granted four patents spanning computational drug design and medical device development.

Researchers from MIT, Massachusetts General Hospital, and Boston University propose a novel "Fund of Adaptive Royalties" (FAR) that finances half the cost of adaptive platform trials in exchange for future drug royalties.

A real-world study by Mass General Brigham's PETAL Consortium demonstrated that the combination of duvelisib and romidepsin achieved a 61% overall response rate in 38 patients with relapsed/refractory T-cell lymphomas.

Alzamend Neuro completed a $5 million private placement months ahead of schedule to fund five Phase II clinical trials of AL001 "Lithium in Brain" studies at Massachusetts General Hospital.

Penumbra has completed enrollment of 100 patients in the pivotal STORM-PE randomized controlled trial, comparing computer assisted vacuum thrombectomy plus anticoagulation versus anticoagulation alone for acute intermediate-high risk pulmonary embolism.